|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, March 13, 2022 ) The Anti-Diarrheal Drugs market size is estimated to reach $186 million by 2027, growing at a CAGR of 4.17% during the forecast period 2022-2027. Diarrhea is defined as the passage of 3 or more liquid stools per day. They can be caused by bacterial infections, allergic reactions, consumption of contaminated food and water, and inflammatory bowel disease. Gastrointestinal drugs can help slow down or stop diarrhea. However, they cannot eliminate the cause of the condition. Some of the most commonly used Anti-Diarrheal Drugs include Bismuth Subsalicylate, Loperamide, and Kaolin-Pectin. The rapid rise in prevalence of food poisoning is driving the market for Anti-Diarrheal Drugs during the forecast period 2022-2027. However, lack of awareness or access to drugs in low and middle-income countries acts as a key challenge for the Anti-Diarrheal Drugs industry.
Anti-Diarrheal Drugs Market Segment Analysis – By Drug Class
Based on Drug Class, the Anti-Diarrheal Drugs Market is segmented into Adsorbent Drugs, Anti Secretory Drugs, Intestinal Flora Modifiers, and Antimotility Drugs. The Antimotility Drugs segment is anticipated to have the largest share of the market in 2021 and is poised to dominate the market during the forecast period 2022-2027. Antimotility Drugs can be further segmented into Codeine, Loperamide, and Diphenoxylate. Antimotility drugs help decrease bowel motility and relieve rectal spasms. Moreover, they also increase the transit time of stool through the bowel, giving more time for the absorption of water and electrolytes. The Intestinal Flora Modifiers segment is projected to grow the fastest at a CAGR of 4.7% owing to the rising consumption of probiotic drinks. They work by supplying beneficial bacteria such as lactobacillus to the GI tract while suppressing the growth of diarrhea-causing bacteria.
Anti-Diarrheal Drugs Market Segment Analysis – By End User
The Anti-Diarrheal Drugs Market based on End Users can be further segmented into Adults, Children, and Others. The Children segment accounted for the largest share of the market in 2021. According to the Centers for Disease Control (CDC), Diarrheal diseases were responsible for around 1 in 9 child deaths worldwide, making diarrhea the second leading cause of death among children under the age of 5. The number of annual cases of deaths among children is estimated to be around 801,000. This is contributing to the growth of the segment as Anti-Diarrheal drugs can help reduce the risk of severe dehydration among patients. However, the adult segment is also anticipated to witness a rapid CAGR of 4.9% during the forecast period 2021-2026 owing to the increase in the prevalence of traveler’s diarrhea.
Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=17439
Report Price: $ 4500 (Single User License)
Anti-Diarrheal Drugs Market Segment Analysis – By Geography
The Anti-Diarrheal Drugs Market based on Geography can be segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. The North American segment is projected to dominate the Anti-Diarrheal Drugs market during the forecast period 2022-2027 with a market share of 34% owing to the presence of highly developed healthcare infrastructure, rising patient awareness levels, the high adoption rate of anti-diarrheal drugs, and growing prevalence of Celiac Disease in the US and Canada. The Asia Pacific region is predicted to register the fastest growth owing to the increase in disposable income and growth in public healthcare infrastructure development. Moreover, the lack of adequate hygiene and sanitation procedures has increased the prevalence of food poisoning cases in major emerging economies such as China and India. This is increasing the demand for anti-diarrheal medication in the region.
Anti-Diarrheal Drugs Market Drivers
Increase in Prevalence of Inflammatory Bowel Disease is Projected to Drive Market Growth
The rise in prevalence of Inflammatory bowel disease (IBD) is driving the market for Anti-Diarrheal Drugs as diarrhea is one of the most common symptoms of the condition. The major forms of IBD include Crohn’s disease and ulcerative colitis. According to the Crohn’s and Colitis Foundation of America, there are around 1.6 million Americans suffering from IBD. The occurrence of the disease increased by around 200,000 since 2011. Each year around 70,000 new IBD cases are diagnosed in the US. Moreover, there are around 80,000 children in the US who are diagnosed with the disease.
The Rise in Food Poisoning is Anticipated to Boost Product Demand
The rapid rise in the prevalence of food poisoning is driving the market for Anti-Diarrheal Drugs. According to the World Health Organization (WHO), around 600 million people become sick after consuming contaminated food and almost 420,000 die every year from food poisoning-related diseases. The annual economic loss associated with food poisoning is estimated to be around $110 billion for low and middle-income countries. Moreover, children under the age of 5 carry almost 40% of the foodborne disease burden with 125,000 deaths annually. Diarrheal disease from food poisoning cause around 550 million people to become sick and 230,000 deaths worldwide every year.
Direct Purchase @ https://www.industryarc.com/purchasereport.php?id=17439
Anti-Diarrheal Drugs Market Challenges
The Adverse Effects of Drugs is Anticipated to Hamper Market Growth
The adverse effects associated with the consumption of Anti-Diarrheal Drugs are anticipated to challenge demand generation. For instance, the consumption of anti-diarrheal drugs for diarrhea caused by bacterial infection can result in the bacterial toxins remaining in the body, which may lead to worsening of symptoms in the future. Moreover, excessive use of the medication can lead to severe constipation. Adsorbent drugs can cause bleeding, constipation, confusion, twitching, and even hearing loss or tinnitus. Major side effects of anti-secretory drugs include headache, anxiety, impotence, blurred vision, hypotension, and tachycardia. Meanwhile, antimotility drug consumption can cause respiratory depression, bradycardia, and anorexia.
Covid-19 Pandemic and Subsequent Restrictions is Projected to Limit Growth Opportunities
The rapid spread of the Covid-19 virus and the surge in the number of infections and deaths owing to the virus has reduced the number of consultation visits by patients suffering from diarrhea. The reduction in hospital visits is owing to the fear of contracting the virus from hospital environments. This is leading to an increase in the purchase and consumption of over-the-counter medications without consulting a doctor, leading to an increased risk of side effects. Moreover, the restrictions regarding traveling have caused more people to replace anti-diarrheal drugs with homemade remedies for the treatment of mild diarrhea. This is leading to a significant reduction in demand. However, these challenges can be overcome through the rising penetration of online pharmacies in developed countries as they provide home delivery of essential drugs.
Anti-Diarrheal Drugs Industry Outlook:
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Anti-Diarrheal Drugs Market. The top 10 companies of the industry include:
1. GlaxoSmithKline
2. Proctor & Gamble
3. Pfizer
4. Actelion
5. Perrigo
6. Lupin
7. Glenmark Pharmaceuticals
8. Sanofi Aventis
9. Merck & Co
10. Novartis
Partnerships/Product Launches:
In March 2021, Lupin Limited announced the launch of the authorized generic version of Alinia (nitazoxanide) Tablets, 500 mg of Romark Laboratories, L.C. The Nitazoxanide Tablets are used for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients aver the age of 12 years.
In May 2019, Proctor & Gamble announced the launch of a new Pepto Bismol product focused on diarrhea relief. P&G is also introducing the first form innovation to the bismuth category in more than 25 years with the launch of Pepto Bismol Liquicaps, which provide the same relief as its liquid counterpart but can be more convenient.
In December 2019, RedHill Biopharma announced that it has initiated the promotion of Aemcolo (rifamycin) in the U.S. for the treatment of travelers’ diarrhea caused by non-invasive strains of Escherichia Coli (E. coli) in adults. RedHill is a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases.
Key Takeaways
Geographically, the North American Anti-Diarrheal Drugs market accounted for the largest share in 2021 owing to the high awareness and adoption rate of Anti-Diarrheal Drugs in the region.
An increase in the cases of Celiac Disease and Irritable Bowel Syndrome is driving the market. However, the side-effects associated with the consumption of these drugs is challenging demand generation.
Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Anti-Diarrheal Drugs Market Report.
Relevant Link:
Inflammatory Bowel Disease Market
https://www.industryarc.com/Report/15917/inflammatory-bowel-disease-market.html
For more Lifesciences and Healthcare Market reports, please click here
About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.
IndustryARC
Venkat Reddy
(+1) 970-236-3677
venkat@industryarc.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
